Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced its foralumab, the world’s only fully human anti-CD3 monoclonal antibody, highlighted in a FORBES article by William A. Haseltine. Foralumab, currently in clinical development, is designed to treat multiple sclerosis and other neurodegenerative diseases. The article emphasizes foralumab's ability to improve tissue remodeling and immune responses, suggesting it could enhance outcomes for COVID-19 patients as well. Phase 2 trials for non-active SPMS are expected to commence in Q3 2023, marking a significant advancement in the company's immunotherapy pipeline.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced a publication in the Proceedings of the National Academy of Sciences detailing the mechanism of action for intranasal foralumab, an immunomodulatory therapy. The study indicates that foralumab increases naïve-like T cells and Tregs while reducing effector T cells. This was observed across diverse patient groups including COVID and multiple sclerosis patients, as well as healthy volunteers. Tiziana plans to file an Investigational New Drug application for Alzheimer's research and initiate Phase 2 trials for non-active Secondary Progressive Multiple Sclerosis by Q3 2023.
Tiziana Life Sciences (TLSA) announced the filing of an Investigational New Drug (IND) application for milciclib combined with gemcitabine aimed at treating non-small cell lung cancer (NSCLC). This Phase 2 IND filing was accomplished with minimal resources and enhances the asset's value. Milciclib has shown safety in 316 advanced solid cancer patients and improved overall survival in Phase 2 thymic cancer trials. The company is also advancing its CNS programs with intranasal foralumab, demonstrating promising data in trials for secondary progressive multiple sclerosis.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) reported significant clinical improvements in the second Expanded Access patient (EA2) with non-active secondary progressive multiple sclerosis (SPMS) after using intranasal foralumab. The patient's Expanded Disability Status Scale (EDSS) score improved from 6.0 to 5.0 since January 2022. The principal investigator emphasized that such improvements in non-active SPMS patients are rare and warrant further Phase 2 trials. Tiziana is prioritizing intranasal foralumab due to promising results, with six patients currently enrolled in the program.
Tiziana Life Sciences (NASDAQ: TLSA) reported its interim results for the six months ending June 30, 2022, highlighting significant developments in its clinical trials and business activities. The FDA approved the enrollment of two more patients for intranasal foralumab under the Expanded Access Program, with promising clinical outcomes showcased. However, a Phase 1b trial for Crohn's disease is on hold, impacting future research timelines. Financially, the company posted a loss of $8.3 million, a decrease from the previous year's $17 million loss, but its cash reserves fell to $26.5 million from $42.2 million, raising concerns over sustainability.
Tiziana Life Sciences Ltd (NASDAQ: TLSA) reported interim results for the six months ending June 30, 2022, highlighting advancements in its therapeutic pipeline for oncology and immune diseases. The company achieved FDA approvals for expanded patient access to its foralumab treatment for Secondary Progressive Multiple Sclerosis (SPMS) and initiated Phase 1b clinical trials in Crohn’s disease. Financially, Tiziana reported a loss of $8.3 million, down from $17.0 million in the prior year, with $26.5 million in cash reserves. Research and development expenses increased to $7.5 million, reflecting continued investment in key programs.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced its participation at the Biotech Showcase and LifeSci Corporate Access Event on January 9-10, 2023, in San Francisco. The Chief Medical Officer, Dr. Matthew Davis, will host institutional investor meetings and present at both events. The Biotech Showcase presentation is scheduled for January 10, 2023, at 11:00 am PT. Tiziana focuses on developing immunomodulation therapies via innovative drug delivery methods, with lead candidates intranasal foralumab and milciclib showing promising clinical results.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) has completed the in-life phase of a 13-week preclinical study on its intranasal foralumab in transgenic HuGEMM CD3 mouse models. The study confirmed that doses up to 50 µg/rodent were well tolerated, with no adverse clinical changes or related fatalities observed. This milestone is crucial for Tiziana as it supports their upcoming FDA Phase 2 meeting request to study foralumab in conditions such as Multiple Sclerosis and Alzheimer’s Disease. Feedback from the FDA is expected in Q1 2023.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) received a 180-day extension from Nasdaq to comply with the minimum bid price rule, now due by June 12, 2023. Initially notified on June 14, 2022, the company had until December 12, 2022, to rectify its bid price deficiency. The extension allows the stock to continue trading on the Nasdaq Capital Market, and compliance can be regained if the stock closes at or above $1.00 per share for ten consecutive business days. Tiziana is focused on developing innovative CNS immunomodulation therapies.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced its 2022 Annual General Meeting scheduled for December 29, 2022. Shareholders must vote by the record date of November 30, 2022. Relevant documents, including the agenda and financial statements, have been sent via mail and are available on the company's website. Tiziana is a clinical-stage biopharmaceutical firm focusing on innovative drug delivery methods for immunotherapy. Its lead candidates include the intranasal foralumab and milciclib, which have shown promising safety and efficacy in clinical studies.